Pre-made Actinium (225Ac) Lintuzumab Satetraxetan benchmark antibody (Whole mAb ADC, anti-CD33 therapeutic antibody, Anti-SIGLEC-3/SIGLEC3/p67 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-717

Pre-made Actinium (225Ac) Lintuzumab Satetraxetan benchmark antibody (Whole mAb ADC, anti-CD33 therapeutic antibody, Anti-SIGLEC-3/SIGLEC3/p67 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-717-1mg 1mg Inquiry
GMP-Bios-INN-717-10mg 10mg Inquiry
GMP-Bios-INN-717-100mg 100mg Inquiry
GMP-Bios-INN-717-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Actinium (225Ac) Lintuzumab Satetraxetan Biosimilar, Whole Mab Adc, Anti-Cd33 Antibody: Anti-SIGLEC-3/SIGLEC3/p67 therapeutic antibody Drug Conjugate
INN Name Actinium (225Ac) Lintuzumab Satetraxetan
TargetCD33
FormatWhole mAb ADC
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesActinium Pharmaceuticals, Inc. (New York NY USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0